CME Feature: Clinical Advances In Bipolar Disorder

Managing Bipolar Depression: Best Practices and Emerging Therapies

CME Information

Providers

Jointly provided by Postgraduate Institute for Medicine and Novus Medical Education in collaboration with Depression and Bipolar Support Alliance.

Postgraduate Institute for Medicine Novus Medical Education Depression and Bipolar Support Alliance

Financial Support

This activity has been supported by an independent educational grant from Allergan, Inc.

Overview

This Clinical Coffee Break webcast is designed to make healthcare providers aware of emerging therapies in the treatment of bipolar depression, particularly those involving the D3 receptor.

Target Audience

This activity has been designed to meet the educational needs of health care professionals involved in the diagnosis, treatment and management of patients with bipolar disorder.

Educational Objectives

Upon completion of this activity, participants will be better able to do the following:

  • Discuss the potential role of D3 receptors in the pathophysiology and treatment of bipolar depression.

Faculty

Roger S. McIntyre, MD, FRCPC
Professor of Psychiatry and Pharmacology
Head, Mood Disorders Psychopharmacology Unit
Chairman and Executive Director, Brain and Cognition Discovery Foundation
University of Toronto
Toronto, Canada

Joint Accreditation Statement

Jointly Accredited Provider

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Novus Medical Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, December 21, 2018 to December 21, 2019.

Method of Participation

There are no fees for participating and receiving CME credit for this activity. To claim credit, participants must complete the following:

  • Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
  • Complete the pre-test.
  • View the webcast.
  • Complete the post-test and evaluation.
  • Physicians who receive a grade of 100% on the post-test and complete the evaluation will receive a CME certificate.
  • All other participants who receive a grade of 100% or better on the post-test and complete the evaluation will receive a Certificate of Participation.

Estimated Completion Time: 15 minutes

Minimum Hardware/Software Requirements

  • Valid email address
  • Broadband internet connection
  • Computer, smartphone, or tablet device running a recent release of a web browser such as Google Chrome, Mozilla Firefox, Apple Safari, or Microsoft Internet Explorer
  • Multimedia playback capability, including speakers or headphones

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Roger S. McIntyre, MD
Consulting & Speakers Bureau: Lundbeck, Janssen, Shire, Purdue, Pfizer, Otsuka, Allergan, Takeda, Neurocrine, Sunovion

Planners and Managers
The PIM planners and managers have nothing to disclose. The Novus Medical Education planner/managers report the following:

  • Steven Scrivner, MPA, CHCP
    Nothing to disclose
  • Megan Maroney, PharmD
    Speakers’ bureau/faculty/peer reviewer: Otsuka-Lundbeck

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CME Inquiries

For all CME certification inquiries, please contact Postgraduate Institute for Medicine at: inquiries@pimed.com or 303-799-1930.

Faculty

Roger S. McIntyre, MD, FRCPC

Roger S. McIntyre, MD, FRCPC

Professor of Psychiatry and Pharmacology

Head, Mood Disorders Psychopharmacology Unit

Chairman and Executive Director, Brain and Cognition Discovery Foundation

University of Toronto

Toronto, Canada